The relationship between serum bilirubin and Crohn's disease. 2014

Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
*Department of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; †IBD Clinical and Research Center, ISCARE I.V.F. Lighthouse, Prague, Czech Republic; ‡Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; §Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Prague, Czech Republic; and ‖4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

BACKGROUND The oxidative stress is thought to play an important role in Crohn's disease (CD). As serum bilirubin represents the major endogenous antioxidant, this article aimed to evaluate in a clinical study, whether serum bilirubin levels and genes affecting its systemic concentrations are associated with CD. METHODS This exploratory case-control study was based on pediatric (n = 119) and adult (n = 504) patients with CD and 370 appropriate healthy control subjects. The (GT)n and (TA)n dinucleotide variations in heme oxygenase 1 (HMOX1) and bilirubin UDP-glucuronosyl transferase (UGT1A1) gene promoters were determined by fragment analysis. Serum bilirubin levels were compared in a subset of 90 cases and 229 controls, for whom biochemical data were available. RESULTS Substantially lower serum bilirubin levels were detected in patients with CD compared with controls (7.4 versus 12.1 μmol/L, P < 10). Serum bilirubin levels were significantly lower in patients with CD within all UGT1A1*28 genotypes (P < 0.05). UGT1A1*28 homozygotes with wild-type NOD2 gene variant exhibited significant delay in CD manifestation (P = 0.004), while the protective effect of UGT1A1*28 homozygosity was lost in those patients with mutated NOD2 gene. No associations between CD risk and individual HMOX1 gene variants were observed. CONCLUSIONS CD is associated with significantly low serum bilirubin levels, most likely as a result of increased oxidative stress accompanying this inflammatory disease. UGT1A1*28 allele homozygosity, responsible for higher bilirubin levels, seems to be an important modifier of CD manifestation.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011401 Promoter Regions, Genetic DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes. rRNA Promoter,Early Promoters, Genetic,Late Promoters, Genetic,Middle Promoters, Genetic,Promoter Regions,Promoter, Genetic,Promotor Regions,Promotor, Genetic,Pseudopromoter, Genetic,Early Promoter, Genetic,Genetic Late Promoter,Genetic Middle Promoters,Genetic Promoter,Genetic Promoter Region,Genetic Promoter Regions,Genetic Promoters,Genetic Promotor,Genetic Promotors,Genetic Pseudopromoter,Genetic Pseudopromoters,Late Promoter, Genetic,Middle Promoter, Genetic,Promoter Region,Promoter Region, Genetic,Promoter, Genetic Early,Promoter, rRNA,Promoters, Genetic,Promoters, Genetic Middle,Promoters, rRNA,Promotor Region,Promotors, Genetic,Pseudopromoters, Genetic,Region, Genetic Promoter,Region, Promoter,Region, Promotor,Regions, Genetic Promoter,Regions, Promoter,Regions, Promotor,rRNA Promoters
D003424 Crohn Disease A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients. Colitis, Granulomatous,Enteritis, Granulomatous,Enteritis, Regional,Ileitis, Regional,Ileitis, Terminal,Ileocolitis,Crohn's Disease,Crohn's Enteritis,Inflammatory Bowel Disease 1,Regional Enteritis,Crohns Disease,Granulomatous Colitis,Granulomatous Enteritis,Regional Ileitides,Regional Ileitis,Terminal Ileitis
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
January 2019, Mediators of inflammation,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
January 2018, PloS one,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
July 2012, Journal of Crohn's & colitis,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
September 2025, BMC gastroenterology,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
January 2016, Zhonghua xin xue guan bing za zhi,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
December 2013, Cardiology research,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
January 2014, International journal of clinical and experimental medicine,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
January 2013, Chinese medical journal,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
January 2015, Postepy w kardiologii interwencyjnej = Advances in interventional cardiology,
Martin Leníček, and Dana Duricová, and Ondrej Hradsky, and Petra Dušátková, and Alena Jirásková, and Milan Lukáš, and Petr Nachtigal, and Libor Vítek
December 2013, Therapeutic advances in cardiovascular disease,
Copied contents to your clipboard!